Last €264.40 EUR
Change Today -1.59 / -0.60%
Volume 0.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 9:45 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

777 Old Saw Mill River Road

Tarrytown, NY 10591

United States

Phone: 914-347-7000

Fax:

Regeneron Pharmaceuticals, Inc. operates as an integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Products The company has three marketed products: EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States, the European Union (EU), Japan, and certain other countries outside the United States for the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO). The company commenced sales of EYLEA for the treatment of wet AMD and for the treatment of macular edema following CRVO following receipt of regulatory approval in the United States. Bayer HealthCare commenced sales of EYLEA for the treatment of wet AMD following receipt of regulatory approvals outside the United States, and for the treatment of macular edema secondary to CRVO in 2013 following receipt of regulatory approvals in the EU and Japan. Bayer HealthCare has additional regulatory applications for EYLEA for the treatment of wet AMD and macular edema secondary to CRVO pending in other countries. The company is collaborating with Bayer HealthCare on the global development and commercialization of EYLEA outside the United States. Bayer HealthCare markets EYLEA outside the United States. It maintains rights to EYLEA in the United States and is entitled to all profits from any such sales. ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, known in the scientific literature as VEGF Trap, which is available in the United States, EU, and certain other countries for treatment, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. The company and Sanofi globally collaborate on the development and commercialization of ZALTRAP. ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children 12 and older. CAPS are a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. The company has 16 product candidates in clinical development, all of which are discovered in its research laboratories. Its Trap-based clinical programs are EYLEA, which is in clinical trials for the treatment of DME and macular edema following BRVO in collaboration with Bayer HealthCare; and ZALTRAP, which is being studied in combination with its angiopoietin-2 inhibitor (nesvacumab) in oncology in collaboration with Sanofi. The company’s antibody-based clinical programs include 14 fully human monoclonal antibody product candidates. The following seven are being developed in collaboration with Sanofi, including Sarilumab (REGN88), an antibody to the interleukin-6 receptor (IL-6R), which is being developed in rheumatoid arthritis and non-infectious uveitis; Alirocumab (REGN727), an antibody to Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which is being developed for low-density lipoprotein (LDL) cholesterol reduction; Dupilumab (REGN668), an antibody to the interleukin-4 receptor alpha (IL-4R), which is being developed in atopic dermatitis, asthma, and nasal polyposis; Enoticumab (REGN421), an antibody to Delta-like ligand-4 (Dll4), a novel angiogenesis target, which is being developed in oncology; Nesvacumab (REGN910), an antibody to angiopoietin-2 (Ang2), another novel angiogenesis target, which is being developed in oncology; REGN1033, an antibody to myostatin (GDF8), which is being developed in skeletal muscle disorders; and REGN2009, an antibody in clinical development against an undisclosed target. The company is developing six antibody product candidates independently, such as REGN1400, an antibody to ErbB3, which is being develop

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €264.40 EUR -1.59

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $168.31 USD -0.86
Allergan Inc/United States $162.11 USD -0.65
BioMarin Pharmaceutical Inc $69.62 USD -1.18
Jazz Pharmaceuticals PLC $162.71 USD -0.40
Vertex Pharmaceuticals Inc $92.80 USD -0.23
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 99.5x
Price/Sales 14.1x
Price/Book 14.8x
Price/Cash Flow 89.3x
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.